France's Sanofi to acquire biotech firm Vicebio for $1.15 billion
Following the acquisition, Vicebio's non-mRNA candidate vaccine for treating respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) will be added to Sanofi's range.
The Vicebio deal includes a potential milestone payment of up to $450 million based on development and research achievements, and is expected to close in the fourth quarter of this year.
Sanofi will also obtain "Molecular Clamp" technology aimed at enabling quicker development of fully liquid combination vaccines that can be stored at standard refrigeration temperatures, eliminating the need for freezing or freeze-drying.
The British company is the latest in a string of acquisitions by Sanofi, which recently finalised an up to $9.5 billion deal for U.S.-based Blueprint Medicines Corporation.
Sanofi said that the acquisition will not impact its annual guidance.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Crypto Insight
4 hours ago
- Crypto Insight
CoinShares secures French MiCA license, cementing EU presence
CoinShares, a major European cryptocurrency investment firm, has secured a license under the local regulatory framework, Markets in Crypto-Assets Regulation (MiCA). CoinShares received the MiCA license through its French subsidiary, CoinShares Asset Management, the company announced on Wednesday. With the license, CoinShares became the 'first continental European regulated asset management company' to be qualified under MiCA, the announcement noted. CoinShares, a major provider of crypto exchange-traded products (ETPs) in Europe, has also been expanding its US presence since acquiring Valkyrie Funds last year. Triple license mix Following the new license acquisition, CoinShares now holds three regulatory licenses in Europe, including MiCA, the Markets in Financial Instruments Directive (MiFID) license and the Alternative Investment Fund Managers Directive (AIFM) license. CoinShares said it's the only continental European asset manager with this triple license, allowing it to offer services across all EU asset classes. CoinShares' MiCA license, issued by the French Autorité des Marchés Financiers (AMF) on Thursday, allows the company to offer portfolio management and advice on crypto assets in the EU. The MiFID license allows it to do the same for traditional financial instruments. The AIFM license authorizes CoinShares to provide services in alternative fund management and delegated management under the EU's Undertakings for Collective Investment in Transferable Securities Directive (UCITS). A milestone for entire EU industry According to CoinShares co-founder and CEO Jean-Marie Mognetti, the MiCA license acquisition marks a major milestone not only for CoinShares, but for the entire crypto industry in Europe. 'For too long, asset managers operating in crypto have been confined to partial or improvised regulatory frameworks,' Mognetti noted, adding that MiCA has brought a 'clear, harmonised structure across the EU.' CoinShares stressed that its MiCA license enables it to provide services across several EU jurisdictions, with operations currently passported in France, Germany, Cyprus, Ireland, Lithuania, Luxembourg, Malta and the Netherlands. The announcement noted the possibility of extending the authorization across all EU member states. CoinShares makes moves in the US Apart from cementing its position as a key industry leader in the EU, CoinShares has also been actively working to compete with peers in the US market after officially entering the market in 2023. Since introducing the CoinShares Bitcoin and Ether ETF (BTF) — a futures ETF tracking the price of Bitcoin and Ether — in the US in October 2021, CoinShares has launched three more crypto funds in the market. The list of CoinShares ETFs currently offered in the US. Source: CoinShares The other funds include the CoinShares Bitcoin Mining ETF (WGMI) launched in February 2022, the spot Bitcoin ETF, CoinShares Bitcoin ETF (BRRR), and the Bitcoin Futures Leveraged ETF (BTFX), launched in January 2024 and February 2024, respectively. Following last year's acquisition of Valkyrie Funds, CoinShares has also been actively applying for other ETF products in the US, including a potential spot XRP (XRP) ETF. Source:
Zawya
4 hours ago
- Zawya
Emirates introduces retrofitted Boeing 777 to Madrid
Emirates has announced it will deploy its newly refurbished Boeing 777 aircraft to/from Madrid starting from September 16. Customers can look forward to an enhanced travel experience with upgraded interiors and premium signature travel touches across all cabins. Madrid is Emirates' first destination in Spain to operate with the airline's next-generation interiors. Emirates' four-class Boeing 777 will operate as flight EK143/EK144. Emirates flight EK143 will depart Dubai at 14:30hrs and arrive in Madrid at 20:20hrs local time. The return flight, EK144 will depart Madrid at 22:05hrs and arrive in Dubai at 7:10hrs local time, the following day. The deployment of Emirates' retrofitted Boeing 777 to Madrid marks a new era of premium travel to the Spanish city - offering customers the airline's award-winning Premium Economy service, newly configured Business Class cabin, and a 'better' travel experience to/from the country. Emirates' newest Boeing 777 cabin interiors include: A refurbished First-Class cabin with upgraded interiors. New Business Class cabin that provides more privacy and comfort for customers with fully lie-flat seats in an updated 1-2-1 seating configuration. Latest Premium Economy cabin which combines accessible luxury with comfort; offering cream leather seats, increased legroom, adjustable headrests, deeper seat recline and raised cushioned leg rests. Spacious Economy Class seats with new design elements. Copyright 2024 Al Hilal Publishing and Marketing Group Provided by SyndiGate Media Inc. (
Gulf Today
5 hours ago
- Gulf Today
5 years after COVID, pharma shares languish
Global healthcare stocks have not been this cheap in decades and fund inflows into the sector are picking up, yet the shares remain in the doldrums, highlighting uncertainty over drug pricing policies since Donald Trump returned to the White House. Pharma companies' earnings outlook is being obscured by concerns over revived "most-favored-nation" drug pricing rules in the lucrative US market and potential 200% tariffs on pharma imports into the US. Money flooded into drugmakers' shares during the COVID-19 pandemic but more recently there has been an exodus as investors shifted into Big Tech, leaving the sector cheap but unloved, reported Reuters. At 15.9 times forward earnings, healthcare trades 11% below its long-term average and 20% below global equities, its steepest discount in 16 years, just above a record discount in 2009, based on LSEG Datastream data. "We've moved from cautious optimism to cautious pessimism," said Stephanie Aliaga, global market strategist at J.P. Morgan Asset Management in New York. "Valuations have gotten even cheaper, but for a reason," she added, referring to intensifying US policy risks. But some investors are starting to look past the Washington policy fog and at long-term positive drivers, such as aging populations, RNA-based therapeutics, and breakthroughs in weight-loss and diabetes drugs, Reuters reported. Alberto Conca, CIO at Swiss wealth manager LFG+ZEST, has been adding exposure to pharma, biotech and medtech in recent weeks, drawn by strong cash-flow yields and the prospect of US rate cuts boosting this rate-sensitive sector. Interest rate cuts typically support healthcare by lowering R&D funding costs and boosting the value of future cash flows. "These are quality companies with good growth and defensive features being priced as if we're heading into an 'Armageddon scenario', which I believe is unlikely," he said. UK-based M&G Investments has also been selectively adding to healthcare, according to its latest allocation report. Healthcare funds have seen net inflows since 2024, more than reversing the outflows from late 2022 through 2023, fund tracker EPFR data shows. Although year-to-date, inflows total $7.2 billion, down 41% from last year. Innovation is accelerating, pipelines are maturing and M&A is showing signs of picking up — yet stock prices are unmoved. Whether that represents a buying opportunity or a value trap hinges on how and when the policy uncertainty clears, investors said. Historically, healthcare has traded at a modest premium to world stocks, thanks to its defensive profile and steady earnings. But that narrative has unravelled under political pressure from Washington and investors' love of Big Tech. Over the past three years, US healthcare has underperformed the S&P 500 by more than 60 percentage points, making it the worst sectoral performer on Wall Street. Its valuation has deepened to a near-record 27% discount, from parity to the S&P in 2023. "Markets don't like uncertainty, and that shows up in valuations," said Eddie Yoon, healthcare sector leader and portfolio manager at Fidelity Investments in Boston. "Being cheap isn't necessarily a reason to buy. You need a catalyst." For now, that catalyst is elusive. The policy uncertainty makes it difficult to forecast future earnings, he said, though he hopes for more clarity by year-end - potentially also paving the way for more M&A in the industry. Talks with the Trump administration have yet to clarify how and when drug prices will fall, executives from Eli Lilly and Merck said at a May industry conference.
